Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.

ABSTRACT:

SUBMITTER: Dang NH 

PROVIDER: S-EPMC6200343 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature